GLP-1 TirzepatideRx

Home News Coverage

Coverage news

Every coverage development we have covered, newest first.

Short answer

3 dated coverage items. Most recent: Medicare GLP-1 Bridge begins dispensing at $50 a month (2026-07-01).

Coverage decides more outcomes than efficacy does. A covered prescription at a modest copay beats a better molecule nobody can afford to keep taking.

Why coverage developments matter here

Coverage tracks the indication written on the prescription rather than the molecule in the vial. The same tirzepatide is routinely covered as Mounjaro for diabetes and excluded as Zepbound for weight management by the same insurer in the same year.

Compounded preparations sit outside all of it. They are a cash market, and no coverage development so far has changed that.

All coverage items

Primary sources

Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.

  1. ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
  2. FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
  3. FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
  4. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
  5. The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.